All-In vs Split Pricing

Two structures that cannot be compared directly

All-in pricing bundles medication, the clinical service and usually shipping into one monthly figure. 13 of the programmes we track work this way, and the number they advertise is broadly the number you pay.

Split pricing charges a programme or membership fee for clinical services and bills medication separately — sometimes through your insurance, sometimes as an additional cash cost. 8 programmes work this way. The advertised figure is the fee, not the cost of treatment.

Comparing an all-in figure against a split fee is the single most misleading thing a pricing table can do, and most published tables do it.

When split pricing is cheaper, and when it is a trap

Split pricing wins decisively when your insurance covers the medication: you pay a modest programme fee and a copay, and the total can fall well below any cash-pay all-in figure. It is the right structure for anyone with a covered indication.

It is a trap when coverage fails. The programme fee continues, the medication arrives at cash price on top, and the combined total can exceed every all-in programme in the market. The question to settle before enrolling is not which is cheaper in the abstract but whether your plan will actually pay.

The commitment layer on top

Some split-pricing programmes add a term. A reported one-year commitment is a hidden cost that never appears in a headline fee, because it converts a monthly decision into an annual one before you know whether the medication suits you.

Ask two things: what is the total in month six including medication, and what happens if I stop in month three.

How we handle this in our tables

Every all-in figure on this site includes medication plus any mandatory recurring fee. Where a programme uses split pricing and does not publish a medication cost we can capture, we publish no all-in figure rather than adding a fee to an unknown. That is why some rows here show a structure and no price: the honest answer is that the total depends on your coverage.

What to ask before you enrol

One question does most of the work: what will I pay in total in month six at 10 mg, including every fee? A programme that answers in one sentence has flat, all-inclusive pricing. A programme that needs three sentences has a structure worth reading carefully. A programme that cannot answer has told you something.

Then four more: which pharmacy fills the prescription, is the prescriber licensed in my state, does the quoted rate hold at renewal, and what is refundable before shipment.

Where these numbers come from

One dataset, captured 2026-08-05, with a verification status on every record. Prices we read at the provider are tagged as such; figures taken from third-party round-ups are tagged separately and treated as indicative. Where sources disagree we show the conflict rather than choosing. The whole file is downloadable.

Why this distinction changes what you pay

Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the cheapest tracked first year at $2,580 and the most expensive.

None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.

How to act on it this week

Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.

Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.

How this connects to what you will actually pay

Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 16 programmes we price, that runs from $215 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.

5 of those programmes charge a recurring platform fee on top of medication and 12 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.

What we could verify and what we could not

11 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.

Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.

The regulatory distinction that sits under all of this

Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.

That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.

Reading a price like a clinician would

A clinician deciding whether a programme is workable asks three questions a price comparison usually skips. Can this patient stay on it long enough to reach a maintenance dose? Is the supply reliable enough that titration will not be interrupted? And is the prescriber reachable when the fourth-week nausea arrives?

Each maps to something checkable before enrolling. Long prepaid terms answer the first badly if money is tight. A single owned dispensing facility answers the second worse than several named partner pharmacies, because a programme with one supply route cannot reroute your prescription. And the care model answers the third: asynchronous messaging is adequate for most titration questions and inadequate for a few.

None of that appears in an advertised price, and all of it decides whether the price you chose is the price you end up paying.

What the GIP arm may be doing

GIP receptor agonism is the pharmacological difference between tirzepatide and the GLP-1-only agents, and its contribution is still being characterised. Proposed mechanisms include effects on adipose tissue insulin sensitivity, on central appetite pathways distinct from the GLP-1 route, and on the tolerability of GLP-1 agonism itself, which would allow effective exposure at doses that would otherwise be poorly tolerated.

This is an area of active research rather than settled science, and anyone stating the mechanism confidently is ahead of the literature. What is established is the outcome difference in the head-to-head trial; the explanation for it is not fully resolved.

The question worth asking before the price question

Whether you have a covered indication. Tirzepatide is approved for chronic weight management and, as Mounjaro, for type 2 diabetes; obstructive sleep apnoea in adults with obesity is an additional route. A covered prescription under a documented indication beats every cash route on this site, frequently by an order of magnitude.

Most people do this backwards: compare cash prices, enrol, then discover an indication they already qualified for. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison table on this site will save you.